Investors didn't like the biopharmaceutical company's updated guidance.Shares of Bristol Myers Squibb (BMY -7.89%) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its first-quarter results before the market opened.Bristol Myers Squibb reported Q1 revenue of $11.9 billion, up 5% year over year. The company posted a loss of $5.89 per share based on generally accepted accounting principles (GAAP) compared to a profit of $1.07 per share in the prior-year perio ...

Bristol-Myers Squibb (NYSE:BMY) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce.Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs. The company is expecting this will save it $1.5 billion per year by 2025.These job cuts come after the company completed recent acquisition of Karuna and RayzeBio. It’s also worth mentioning that Bristol-Myers Squibb’s Q1 earnings repor ...

For the quarter ended March 2024, Bristol Myers Squibb (BMY) reported revenue of $11.87 billion, up 4.7% over the same period last year. EPS came in at -$5.89, compared to $2.05 in the year-ago quarter.The reported revenue represents a surprise of +3.57% over the Zacks Consensus Estimate of $11.46 billion. With the consensus EPS estimate being -$4.55, the EPS surprise was -29.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile • First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange) ◦ Growth Portfolio Revenues were $4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) • Strengthened Long-Term Growth Profile Through Completion of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune Transacti ...

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023.Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth.But the pharmaceutical company swung to a quarterly loss due to one-time charges related to its recently closed deals. It also launched a program to cut $1.5 billion in costs by 2025, and said it woul ...

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2024 results on Apr 25, before market open. In the previously reported quarter, the company’s earnings beat estimates by 11.84%.Factors at PlayTotal revenues in the first quarter are likely to have been boosted by growth in in-line product revenues and new product portfolio revenues. The Zacks Consensus Estimate for total revenues in the first quarter is pegged at $11.4 billion.Increased sales of the key immuno-oncology drug Opdivo on c ...

DNY59 We previously discussed Bristol Myers Squibb Company (NYSE:BMY) in December 2023, discussing why our previous Hold rating had proven to be prudent, with the stock losing -12.35% of its value since then. Combined with the sustained top-line erosion from Revlimid's LOE, upcoming Eliquis LOE by 2026, and the potential balance sheet deterioration after the aggressive M&A activities, we believed that it might be more prudent to observe the stock's movement for a little longer. In this article, we shall dis ...

These stocks pay between 3.2% and 6.7% in dividends.What's better than a high-yielding dividend stock? A high-yielding dividend stock that's trading at a dirt-cheap price. As long as the underlying business is in strong shape, buying a cheap dividend stock can help maximize your long-term profits as you benefit from both the stock rising in value, assuming it rallies, and from the dividend income you'll earn from holding it.Bristol Myers Squibb (BMY 1.30%), Verizon Communications (VZ 0.90%), and ExxonMobil ...

The U.S. stock market continues to climb the wall of worry, despite persistent inflation and heightened geopolitical risks. The S&P 500 has returned 26% in the past 12 months, while the Wilshire 5000 index (a broader gauge of the total U.S. stock market) has gained 23% in the past year, not including dividends.With the market’s strong rally, dividend yields have sunk. The S&P 500 currently yields just 1.4% right now. Rising valuations and falling dividend yields have made many stocks overvalued.However, the ...

These income stocks look like good options at current levels.Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long periods -- that's even better. A number of dividend stocks on the market fit this description.Let's consider two in the healthcare sector: Bristol Myers Squibb (BMY -0.52%) and Novar ...